Drug intelligence / Profile preview

TCR-T014

Development stage: Preclinical
Lead developer: Protheragen
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

TCR-T014 is a T-cell receptor engineered T-cell (TCR-T) therapy being developed by Protheragen for the treatment of HPV-16 positive cervical cancer. The therapy involves engineering a patient's own T cells to express a specific T-cell receptor that recognizes antigens derived from the Human Papillomavirus type 16 (HPV-16), which is a primary driver of cervical malignancy. By targeting HPV-16 specific epitopes presented on the surface of cancer cells, TCR-T014 aims to selectively eliminate tumor cells while sparing healthy tissue. It is currently in the discovery phase of development.

Targets

Human papillomavirus type 16 E6/E7-derived peptide-HLA class I complex

Beyond the preview

Go deeper on TCR-T014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCR-T014.

Explore the full profile